Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: May 29, 2023

Details for Patent: 10,407,393

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 10,407,393 protect, and when does it expire?

Patent 10,407,393 protects LENVIMA and is included in one NDA.

This patent has thirty-three patent family members in twenty-three countries.

Summary for Patent: 10,407,393

Title:	High-purity quinoline derivative and method for manufacturing same
Abstract:	Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less. ##STR00001##
Inventor(s):	Nakamura; Taiju (Kamisu, JP), Abe; Taichi (Kamisu, JP), Miyashita; Yusuke (Kamisu, JP), Kuroda; Hirofumi (Kamisu, JP), Ayata; Yusuke (Kamisu, JP), Akao; Atsushi (Kamisu, JP)
Assignee:	Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	16/229,805
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,407,393
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 10,407,393

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,407,393

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2014-174062	Aug 28, 2014
Japan	2015-034729	Feb 25, 2015

International Family Members for US Patent 10,407,393

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	101695	⤷ Try a Trial
Australia	2015309862	⤷ Try a Trial
Brazil	112017002827	⤷ Try a Trial
Canada	2957005	⤷ Try a Trial
China	106660964	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Dow

Mallinckrodt

Baxter

Merck

Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.